MOR News and Press, MorphoSys AG From 03/15/23

2023-03-15 16:20:36 ET MorphoSys press release ( NASDAQ: MOR ): FY GAAP EPS of €8.93. Revenue of €81.6M (+54.3% Y/Y). Monjuvi U.S. net product sales US$ 80m to 95m For further details see: MorphoSys GAAP EPS of €8.93, reven...

– Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 – Monjuvi ® U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9 million) for the full year of 2022 ...

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and...

MorphoSys AG ( NASDAQ: MOR ) ( OTCPK:MPSYF ) has decided to terminate its pre-clinical research programs in a bid to optimize its cost structure and focus on its mid- to late-stage cancer pipeline, the German biotech announced Thursday. “While the data from these pre-clinic...

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs are promising, MorphoSys would ne...

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) (the " Company ") today announces that it will stop work and operations on its pre-clinical research programs to optimize its cost structure. As a result, MorphoSys will reduce its workforce at the Company's headqu...

Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...

Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...

Summary CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40% growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTIC’s Vonjo (Pacritinib) is a differentiated late-stage JAK2/IRAK4/FLT3/CSF1R inhibitor for the treat...

MUNICH, GERMANY / ACCESSWIRE / January 9, 2023 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxoli...